Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Both platforms are targeting multi-billion dollar markets. The recent capital increase will be used to advance both platforms to the next stage of development and investment in corporate infrastructure.
26 Sep 2016
New frontiers in T-cell activation and targeting
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
New frontiers in T-cell activation and targeting
Scancell Holdings Plc (SCLP:LON) | 10.2 0 0.0% | Mkt Cap: 95.1m
- Published:
26 Sep 2016 -
Author:
Martin Hall -
Pages:
56
Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Both platforms are targeting multi-billion dollar markets. The recent capital increase will be used to advance both platforms to the next stage of development and investment in corporate infrastructure.